If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.
Published: June 5, 2021 at 09:00PM
from NYT Health https://ift.tt/3z8ZOEC